[{"name":"139O - Final results of the double-blind placebo (PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for inoperable locally advanced\/metastatic triple-negative breast cancer (mTNBC) (ID 453)","mode":"playlist","is_cme":false,"info":{"presentation":"139O - Final results of the double-blind placebo (PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for inoperable locally advanced\/metastatic triple-negative breast cancer (mTNBC) <small>(ID 453)<\/small>","session":"Proffered Paper session 1 <small>(ID 5)<\/small>","presenter":"Rebecca Dent<small> (Singapore, Singapore)<\/small>","photo":null},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/breast2020\/5\/v\/453_1p.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/breast2020\/5\/v\/453_1p.mp4","cover":"","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/breast2020\/5\/v\/453_1p.vtt","thumbnails":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/breast2020\/5\/v\/453_1p-thumbnails.vtt"}]}]{"provider":"CTI","provider_live":0,"type":1,"code":"9L2408P02Vk"}